Loading company…
Memo Therapeutics AG develops human-derived monoclonal antibodies, including AntiBKV for BK virus in kidney transplant patients.
The company uses its DROPZYLLA technology for antibody screening and has a partnership with Ono Pharmaceutical. Founded in 2012 by Christoph Esslinger, it is based in Schlieren, Switzerland, and is at the Series C stage. In May 2024 it raised CHF 20 million in Series C funding from Ysios Capital Partners and Kurma Partners, with participation from BB Pureos Bioventures, Swisscanto, Vesalius Biocapital and others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in